As a wholly owned subsidiary of Lupin Limited, the company is creating a customer-facing organization with an external service and trusted outsourcing partner mindset.
The plant adds 100 cubic meters of reactor capacity for complex, high-containment drug substance production to bolster the CDMO’s small molecule services.
The investment at Eisai’s Hatfield facility will add cold-chain packaging and logistics capabilities for injectable medicines, including Alzheimer’s therapy lecanemab.
